citric acid, anhydrous has been researched along with Delayed Graft Function in 3 studies
Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.
citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.
Delayed Graft Function: General dysfunction of an organ occurring immediately following its transplantation. The term most frequently refers to renal dysfunction following KIDNEY TRANSPLANTATION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Z | 1 |
| Yang, H | 1 |
| Zhao, C | 1 |
| Wei, J | 1 |
| Wang, J | 1 |
| Han, Z | 1 |
| Tao, J | 1 |
| Xu, Z | 1 |
| Ju, X | 1 |
| Tan, R | 1 |
| Gu, M | 1 |
| Sui, M | 1 |
| Zhang, L | 1 |
| Yang, J | 1 |
| Zeng, L | 1 |
| Zhao, W | 1 |
| Zhu, Y | 1 |
| Robert, R | 1 |
| Guilhot, J | 1 |
| Pinsard, M | 1 |
| Longeard, PL | 1 |
| Jacob, JP | 1 |
| Gissot, V | 1 |
| Hauet, T | 1 |
| Seguin, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant[NCT04529005] | Phase 4 | 20 participants (Actual) | Interventional | 2020-08-13 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Duration of vasopressor usage while in the operating room measured in hours of usage presented as median and IQR. (NCT04529005)
Timeframe: Duration of usage during the transplant surgery - presented in hours
| Intervention | hours (Median) |
|---|---|
| Angiotensin II (Giapreza) | 1 |
The presence of arrhythmia was confirmed via EKG, flowsheet, or note documentation from the electronic medical record. (NCT04529005)
Timeframe: From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Angiotensin II (Giapreza) | 1 |
The presence of Delayed Graft Function was captured for each patient and defined by the need for renal replacement therapy up to 7 days post-operative. (NCT04529005)
Timeframe: From post-op to 7 days post-op
| Intervention | Participants (Count of Participants) |
|---|---|
| Angiotensin II (Giapreza) | 2 |
The presence of post-operative fungal infections were captured prior to discharge as documented by the clinical care team in the electronic medical record. (NCT04529005)
Timeframe: From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Angiotensin II (Giapreza) | 0 |
The presence of hyperglycemia was captured for each patient and was determined by those patients requiring the use of an insulin infusion after their transplant surgery. (NCT04529005)
Timeframe: From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Angiotensin II (Giapreza) | 1 |
The presence of digital or other peripheral/visceral ischemia was captured from reviewing chart documentation for each patient. (NCT04529005)
Timeframe: From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Angiotensin II (Giapreza) | 0 |
Incidence of venous or arterial thrombosis occurring during the hospitalization for kidney transplant (captured by ultrasound or other diagnostic imaging) (NCT04529005)
Timeframe: From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Angiotensin II (Giapreza) | 0 |
1 trial available for citric acid, anhydrous and Delayed Graft Function
| Article | Year |
|---|---|
A new HC-A II solution for kidney preservation: A multi-center randomized controlled trial in China.
Topics: Adenine; Adolescent; Adult; China; Citric Acid; Cold Ischemia; Delayed Graft Function; Double-Blind | 2014 |
2 other studies available for citric acid, anhydrous and Delayed Graft Function
| Article | Year |
|---|---|
Proton Nuclear Magnetic Resonance (¹H-NMR)-Based Metabolomic Evaluation of Human Renal Allografts from Donations After Circulatory Death.
Topics: Adult; Allografts; Betaine; Citric Acid; Delayed Graft Function; Female; Glucose; Humans; Kidney; Ki | 2017 |
A pair analysis of the delayed graft function in kidney recipient: the critical role of the donor.
Topics: Adolescent; Adult; Age Factors; Aged; Biomarkers; Brain Death; Child; Citric Acid; Delayed Graft Fun | 2010 |